Salute e Benessere
EnChannel Medical Raises $82.2M in Oversubscribed Series-B Financing to Advance Full-Chamber 5D Atrial Fibrillation Mapping and Personalized Pulsed-Field Ablation Therapy
said , CEO of EnChannel Medical. " "
Founded in 2020 by a team of seasoned electrophysiology innovators from both the United States and China , EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation.
Headquartered in Guangzhou , with an R&D subsidiary in Irvine, California , EnChannel is well positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions.
For more information, visit http://www.enchannel.com and follow us on LinkedIn.
The DePolar® Mapping System and the NanoAblate® PFA System are investigational devices and are limited by federal (or United States) law to investigational use.
Bradley Wegrzynowicz
(610)462-0197
Bradley.wegrzynowicz@enchannel.com
Logo - https://mma.prnewswire.com/media/2677615/EnChannel_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/enchannel-medical-raises-82-2m-in-oversubscribed-series-b-financing-to-advance-full-chamber-5d-atrial-fibrillation-mapping-and-personalized-pulsed-field-ablation-therapy-302443524.html